Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)

NCT03713593 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

794

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: lenvatinib
BIOLOGICAL: pembrolizumab
DRUG: saline placebo

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]